



INTRAVENOUS ALTEPLASE 3-6 HOURS VERSUS 0-3 HOURS IN ACUTE ISCHEMIC STROKE, AN EGYPTIAN BASED STUDY

Thesis

*Submitted for Partial Fullfillment of Master Degree
in Intensive Care*

By

Essam Mohamed Ezzaat Ali

M.B.B.Ch (Faculty of Alexandria – Alexandria University, 1993)

Supervised by

Prof./ Waleed Mohamed Abd El-Mageed

*Professor of Anesthesiology, Intensive Care and Pain Management
Faculty of Medicine - Ain Shams University*

Dr/ Rania Magdy Mohamed

*Assistant Professor of Anesthesiology, Intensive Care and Pain Management
Faculty of Medicine - Ain Shams University*

Dr/ Mohamed Moien Mohamed

*Lecturer of Anesthesiology, Intensive Care and Pain Management
Faculty of Medicine - Ain Shams University*

*Faculty of Medicine
Ain Shams University*

2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof./ Waleed Mohamed Abd El-Mageed**, Professor of Anesthesia, Intensive Care and Pain Management - Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr/ Rania Magdy Mohamed**, Assistant Professor of Anesthesia, Intensive Care and Pain Management, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr/ Mohamed Moien Mohamed**, Lecturer of Anesthesia, Intensive Care and Pain Management, Faculty of Medicine, Ain Shams University, for his great help, active participation and guidance.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Essam Mohamed Ezzaat Ali

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations	iv
Introduction	1
Aim of the Work.....	3
Review of Literature	
Ischemic Stroke	4
Ischemic Stroke Classification, diagnosis and mangement	19
Pharmacology of Intravenous Thrombolytic Therapy	40
Intravenous Thrombolytic Therapy in Acute Ischemic Stroke	46
Patients and Methods	58
Results	67
Discussion	84
Summary	99
Conclusion.....	102
References	103
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):		26
Table (2):	Comparison between the 2 groups as regards basic clinical data	67
Table (3):	Comparison between the 2 groups as regards risk factors.....	68
Table (4):	Comparison between the 2 groups as regards baseline neurological data	69
Table (5):	Comparison between the 2 groups as regards baseline laboratory data.....	70
Table (6):	Comparison between the 2 groups as regards baseline radiological data	71
Table (7):	Comparison between pre and post-infusion neurological and radiological assessments in group A	72
Table (8):	Comparison between pre and post-infusion neurological and radiological assessments in group B	73
Table (9):	Comparison between the 2 groups as regards pre and post-infusion neurological assessments.....	74
Table (10):	Comparison between the 2 groups as regards disability and neurological improvement outcomes	76
Table (11):	Multiple regression model for the Factors affecting post-infusion (24-h) NIHSS score.....	78
Table (12):	Multiple regression model for the Factors affecting post-infusion (30-days) mRS score	79

List of Tables (cont...)

Table No.	Title	Page No.
Table (13):	Logistic regression model for the Factors affecting disability occurrence	80
Table (14):	Logistic regression model for the Factors affecting mortality occurrence	81
Table (15):	Logistic regression model for the Factors affecting neurological improvement occurrence	82
Table (16):	Roc-curve of early Alteplase infusion (0-3h), to predict neurological improvement occurrence	83

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Normal cerebral autoregulation and its disturbance during acute ischemic stroke.	12
Figure (2):	Effects of decreased cerebral blood flow on vital brain functions.....	12
Figure (3):		14
Figure (4):	The most frequent sites of arterial and cardiac abnormalities causing ischemic stroke.....	18
Figure (5):	Frontal view of the carotid arteries, vertebral arteries, and intracranial vessels and their communication with each other via the circle of Willis.....	20
Figure (6):	CT scan showing a very prominent hyperdense left MCA.....	29
Figure (7):	DWI (a) and FLAIR (b) of an acute stroke patient <3 h after symptom onset.....	30
Figure (8):	Carotid duplex ultrasonography of the right internal carotid artery	31
Figure (9):	Serial NIHSS assessments in the 2 groups.	74
Figure (10):	Serial mRS assessments in the 2 groups.	75
Figure (11):	Comparison between the 2 groups as regards mortality.	76
Figure (12):	ROC curve of early Alteplase infusion (0-3h) for neurological improvement prediction.	83

List of Abbreviations

Abb.	Full term
<i>ACA</i>	<i>Anterior cerebral artery</i>
<i>ACOM</i>	<i>Anterior communicating artery</i>
<i>ADC</i>	<i>apparent diffusion coefficient</i>
<i>AHA</i>	<i>American heart association</i>
<i>AHA/ASA</i>	<i>American Heart Association / American Stroke Association</i>
<i>AIS</i>	<i>Acute ischemic stroke</i>
<i>ATLANTIS</i>	<i>The Alteplase Thrombolysis for Acute Non Interventional Therapy in Ischemic Stroke</i>
<i>BA</i>	<i>Basilar artery</i>
<i>BABO</i>	<i>Basilar artery atheromatous branch occlusive disease</i>
<i>BP</i>	<i>Blood pressure</i>
<i>CBC</i>	<i>Complete blood count</i>
<i>CBF</i>	<i>Cerebral blood flow</i>
<i>CPP</i>	<i>Cerebral perfusion pressure</i>
<i>CSD</i>	<i>Cortical spread depression</i>
<i>CSF</i>	<i>Cerebrospinal fluid</i>
<i>CT brain scan</i>	<i>Computed tomography brain scan</i>
<i>CTA</i>	<i>Computed Tomography Angiography</i>
<i>DEDAS</i>	<i>Dose Escalation study of Desmoteplase in Acute ischemic Stroke</i>
<i>DIAS</i>	<i>Desmoteplase in Acute Ischemic Stroke</i>
<i>DSPA1</i>	<i>D rotundus salivary plasminogen activator alpha-1</i>
<i>DWI</i>	<i>diffusion weighted image</i>
<i>ECASS</i>	<i>The European Cooperative Acute Stroke Study</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>EHRA-ESC.....</i>	<i>European Heart Rhythm Association / European Society of Cardiology</i>
<i>ESR.....</i>	<i>Erythrocyte sedimentation rate</i>
<i>FDA.....</i>	<i>Food and Drug administration</i>
<i>FDP.....</i>	<i>Fibrin degradation products</i>
<i>FLAIR.....</i>	<i>Fluid-attenuated inversion recovery</i>
<i>GBD</i>	<i>Global Burden of Disease</i>
<i>ICA.....</i>	<i>Internal carotid artery</i>
<i>ICH</i>	<i>Intra-cerebral hemorrhage</i>
<i>IST-3.....</i>	<i>The third International Stroke Trial</i>
<i>IV</i>	<i>Intravenous</i>
<i>LDL-C.....</i>	<i>Low-density lipoprotein cholesterol</i>
<i>MAP</i>	<i>Mean arterial blood pressure</i>
<i>MCA.....</i>	<i>Middle cerebral artery</i>
<i>MRI.....</i>	<i>Magnetic resonance image</i>
<i>mrs.....</i>	<i>Modified Rankin Scale</i>
<i>NIHSS</i>	<i>National Institutes of Health Stroke Scale</i>
<i>NINDS.....</i>	<i>The National Institute of Neurological Disorders and Stroke</i>
<i>OSA.....</i>	<i>Obstructive sleep apnea</i>
<i>PAO.....</i>	<i>Proximal arterial occlusion</i>
<i>PCA.....</i>	<i>Posterior cerebral artery</i>
<i>PCIS.....</i>	<i>Posterior circulation ischemic stroke</i>
<i>PCOM</i>	<i>The posterior communicating artery</i>
<i>PIDs.....</i>	<i>Peri-infarct depolarizations</i>
<i>REGARDS</i>	<i>Reasons for Geographic and Racial differences in Stroke</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>rt-PA</i>	<i>Recombinant Tissue Plasminogen Activator</i>
<i>SITS</i>	<i>The Safe Implementation of Thrombolysis in Stroke</i>
<i>SK</i>	<i>Streptokinase</i>
<i>TIA</i>	<i>Transient ischemic attack</i>
<i>UFH</i>	<i>Unfractionated heparin</i>
<i>UK</i>	<i>Urokinase</i>
<i>VA</i>	<i>Vertebral artery</i>

INTRODUCTION

Stroke is the number 4 cause of death and a leading cause of long-term disability in the United States. Roughly 6.8 million Americans 20 years and older have had a stroke, and an additional 4 million individuals are projected to have a stroke by the year 2030 (*Go et al., 2014*). About 780,000 strokes are estimated to occur annually in the United States (*Rosamond et al., 2008*).

87% of all strokes are ischemic (e.g., due to large artery thrombosis or cardiogenic embolism). As a result, much attention has been focused on developing treatment strategies for this stroke subtype.

In Egypt, the most populated nation in the Middle East, the overall crude prevalence rate of stroke is high (963/100,000 inhabitants). The official national statistics indicate that diseases of the circulatory system, including stroke, are the primary cause of death in Egypt (*Abdullah et al., 2014*).

Alteplase (recombinant tissue-type plasminogen activator; rt-PA), is a serine protease produced by recombinant DNA technology. The molecule consists of a single polypeptide chain of 527 amino acids which is chemically identical to human endogenous t-PA. Promotes thrombolysis by converting plasminogen to plasmin; plasmin degrades fibrin and fibrinogen (*Collen et al., 1989*).

The Food and Drug Administration (FDA) approval in June 1996 of intravenous recombinant tissue-type plasminogen activator (rt-PA) for patients with acute ischemic stroke treated within 3 hours of symptom onset marked a historic first step in treating this devastating disease. This approval was primarily based on the results of the National Institute of Neurologic Disorders (NINDS) trials.

Recanalization documented within 6 hours of onset tends to be strongly associated with good clinical outcomes, with a 4- to 5-fold increase in the odds of good final functional outcome (*Chalela et al., 2007*).

In June 2012, Sandercock and colleagues published a meta-analysis of 12 intravenous rtPA trials that had enrolled 7012 patients up to 6 hours from symptom onset. The results confirmed the benefits of intravenous rtPA administered within 6 hours from symptom onset. Utilization of reperfusion therapies for stroke remains <1% in Egypt. Among contributing factors are country-specific problems such as poor public and physician awareness, the affordability of the drugs, and availability of experienced personnel and resources.

AIM OF THE WORK

To assess safety and effectiveness of IV alteplase given 3-6 hours versus 0-3 hours after acute ischemic stroke

Chapter 1

ISCHEMIC STROKE

Definition

Stroke is defined as an episode of focal neurologic (brain, retina, spinal cord) dysfunction (even if less than 24 h duration) in which the autopsy, computed tomography (CT) brain scan, or magnetic resonance imaging (MRI) brain scan shows features consistent with focal brain infarction or hemorrhage (*Easton et al., 2009*). Ischemic stroke is responsible for about 80% of all strokes intra cerebral hemorrhage (ICH) for 15% and subarachnoid hemorrhage (SAH) for 5% (*Moinuddin et al., 2015*).

Epidemiology

Stroke is the number 4 cause of death and a leading cause of long-term disability in the United States. Roughly 6.8 million Americans 20 years and older have had a stroke, and an additional 4 million individuals are projected to have a stroke by the year 2030 (*Go et al., 2013*). About 780,000 strokes are estimated to occur annually in the United States (*Rosamond et al., 2008*).

The importance of addressing stroke through well-devised epidemiologic studies was underscored by the Global Burden of Disease 2013 Study (*GBD, 2013*).

The GBD 2013 used world mapping to visualize stroke burden and its trends in various regions and countries using epidemiologic measures of age-standardized incidence, mortality, prevalence, disability-adjusted life years, and years lived with disability associated with stroke from 1990 to 2013 (*Feigin et al., 2015*).

Their findings showed that the absolute number of people affected by stroke substantially increased across all countries in spite of dramatic declines in age-standardized incidence, prevalence, mortality rates, and disability. Population growth and aging have played an important role in the observed increase in stroke (*Feigin et al., 2015*).

The prevalence of non-fatal stroke in Egypt is 5.6 per 1,060 populations. This prevalence lies within the lower range of that recorded in developing countries (5-10 per 1,000). This is similar to that found in India (5.5 per 1,000), but higher than recorded in Saudi Arabia (1.8 per 1,000) (*El-Talawy et al., 2013*).

Risk factors of stroke

When we examine persons with stroke, we often find risk factors. Although one may look for “the cause,” or the direct mechanism of stroke, such as atherosclerotic plaque or embolic source, common risk factors contribute a significant extent to the underlying processes that lead to strokes. Treatment of risk